Skip to main content

Table 1 Associations between ALK rearrangement and the clinicopathologic characteristics of 487 patients with non-small cell lung cancer (NSCLC)

From: Clinicopathologic characteristics and therapeutic responses of Chinese patients with non-small cell lung cancer who harbor an anaplastic lymphoma kinase rearrangement

Characteristic

Number of patients (%)

ALK rearrangement [cases (%)]

P

Negative

Positive

Total

487

443 (91.0)

44 (9.0)

 

Age

 ≤58 years

261 (53.6)

229 (51.7)

32 (72.7)

0.008

 >58 years

226 (46.4)

214 (48.3)

12 (27.3)

 

Sex

 Male

303 (62.2)

279 (63.0)

24 (54.5)

0.271

 Female

184 (37.8)

164 (37.0)

20 (45.5)

 

Histological type

 Adenocarcinoma

382 (78.4)

339 (76.5)

43 (97.7)

0.001

 Others

105 (21.6)

104 (23.5)

1 (2.3)

 

Differentiation

 Well

206 (42.3)

187 (42.2)

19 (43.2)

0.901

 Poor

281 (57.7)

256 (57.8)

25 (56.8)

 

Clinical stage

 I + II

226 (46.4)

213 (48.1)

13 (29.5)

0.019

 III + IV

261 (53.6)

230 (51.9)

31 (70.5)

 

Smoking history

 Non-smoker

239 (49.1)

207 (46.7)

32 (72.7)

0.001

 Smoker

248 (50.9)

236 (53.3)

12 (27.3)

 

EGFR mutation status

    

 Negative

328 (67.4)

285 (64.3)

43 (97.7)

<0.001

 Positive

159 (32.6)

158 (35.7)

1 (2.3)

 
  1. ALK anaplastic lymphoma kinase, EGFR epidermal growth factor receptor.
  2. All values are presented as number of patients followed by percentages in the parentheses.